Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
β-SPECIFIC 4 Patients: Study of Pediatric Efficacy and Safety of Canakinumab in Systemic Juvenile Idiopathic Arthritis
2013-004867-29Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA) and juvenile idiopathic arthritis (JIA), sponsored by Novartis. Primary endpoint: Proportion of patients maintaining remission on reduced canakinumab regimen. Started Jul 2014; status: completed.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2013-004867-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004867-29.